

# Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells

Innovo Therapeutics, Inc.



IMMUNOLOGY	Non-Clinical
Product Type	Small molecule
Indication	Ulcerative Colitis
Target	Not opened
MoA(Mechanism of Action)	<p>Inhibition of glycogen metabolism by INV-101 leads to</p> <ul style="list-style-type: none"> <li>• significantly attenuate proliferation of immune cells</li> <li>• decrease pro-inflammatory cytokine production in serum</li> <li>• significantly suppress ROS (Reactive oxygen species) resulting in tissue injury</li> </ul>
Competitiveness	<p>Competitive Efficacy</p> <ul style="list-style-type: none"> <li>• New small molecule with novel mechanism of action</li> <li>• Anti inflammatory effects by modulating glycogen metabolism of immune cells &amp; ROS scavenging</li> <li>• Potential competitive efficacy compared to pan-Jak inhibitor Superior Safety</li> <li>• Proven safe target in diabetes</li> <li>• No pan-immunosuppression</li> <li>• Broad safety margin in animal model</li> </ul>
Development Stage	Non-Clinical
Route of Administration	Oral